µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ÀÓ»ó ¾÷¹«º°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By Therapeutic Area, By End-use (Healthcare Companies), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1529670
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 139¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 22.7%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹Ãø ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ÇコÄÉ¾î °ü·Ã ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀÌ¼Ç ¹× ±â±âÀÇ Ã¤Åà Áõ°¡, ´Ù¾çÇÑ Ä¡·á ¸ñÀû¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½º¸¶Æ®Æù »ç¿ë Áõ°¡, »õ·Î¿î ¿þ¾î·¯ºí ±â¼úÀÇ µµÀÔ µîÀÌ ÀÖ½À´Ï´Ù. ¾×¼¾Ãò¾î Çコ ¾Ø ¶óÀÌÇÁ»çÀ̾𽺠ÀͽºÇǸ®¾ð½º Á¶»ç¿¡ µû¸£¸é, ¹Ì±¹ °ÅÁÖÀÚÀÇ 26%´Â ÇコÄÉ¾î ¾ÖÇø®ÄÉÀÌ¼Ç ¹× ±â±â µµÀÔÀ¸·Î ÀÎÇØ ÇコÄÉ¾î ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾ú´Ù°í ÀÀ´äÇß½À´Ï´Ù.

¶ÇÇÑ, Á¤ºÎ ±â°üµéÀº COVID-19 »çÅ·ΠÀÎÇÑ Å« ¾î·Á¿òÀ¸·Î ÀÎÇØ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÑ ¾à¹° °³¹ß¿¡ °ü½ÉÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù ¾Æ½ºÆ®¶óÁ¦³×Ä«´Â ¿µ±¹¿¡ º»»ç¸¦ µÐ ÀÇ·á ±â¼ú ±â¾÷ ÈÞ¸¶ Å×¶óǻƽ½º(Huma Therapeutics)¿Í Çù·ÂÇÏ¿© ´Ù¾çÇÑ Ä¡·á ÁúȯÀ» À§ÇÑ SaMD(Software as a Medical Device) ÄÄÆÐ´Ï¾ð ¾ÖÇø®ÄÉÀ̼ÇÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ ¾ÖÇø®ÄÉÀ̼ÇÀº ¿¹Ãø ¾Ë°í¸®Áò, µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿, ½ÇÁ¦ µ¥ÀÌÅ͸¦ °áÇÕÇÏ¿© °³¹ßµÆ½À´Ï´Ù.

Á¦¾à ¿¬±¸ ºñ¿ëÀÇ »ó½Â°ú »ó´ëÀûÀ¸·Î ³·Àº ¼º°ø·ü·Î ÀÎÇØ µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿(DBM)°¡ ºü¸£°Ô »ý¼ºµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ DBMÀº Ãʱ⠾ËÃ÷ÇÏÀ̸Ӻ´À̳ª Ä¡¸Å¿Í °°Àº ƯÁ¤ ºÐ»êÇü ÀÓ»ó ¿¬±¸ ºÐ¾ß¿¡ ÁýÁßÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ¿© ÀǾàǰ °³¹ß ½Ã°£, ½ÇÆÐÀ² ¹× ºñ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ´Ù°í µðÁöÅÐ ¼Ö·ç¼Ç ȸ»ç healthxlÀÇ ºí·Î±×¿¡ µû¸£¸é, µðÁöÅÐ ÀÇÇÐ Çùȸ(DiME)´Â ÃÖ±Ù µðÁöÅÐ ÀÇÇÐ Çùȸ(DiME)¸¦ ¼³¸³Çß½À´Ï´Ù. )´Â ÃÖ±Ù À϶óÀÌ ¸±¸®, ¸ÓÅ©, ¹ÙÀÌ¿ÀÁ¨°ú °°Àº ÃÖ°íÀÇ Á¦¾à»çµéÀ» ¸ð¾Æ Ä¡¸Å¿Í ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ´ëÇÑ ÀÏ·ÃÀÇ ÇÙ½É Ç¥ÁØ µðÁöÅÐ ¿£µåÆ÷ÀÎÆ®¸¦ È®ÀÎÇß½À´Ï´Ù. ÀÌ´Â Àΰ£À» ´ë»óÀ¸·Î ÇÑ »õ·Î¿î Ä¡·áÁ¦ÀÇ À¯È¿¼º Æò°¡ ¹®Á¦¸¦ ÇØ°áÇϰí, »õ·Î¿î Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ëÀ» ÁÙÀ̱â À§ÇÑ °ÍÀÔ´Ï´Ù.

Àü ¼¼°è Áö¿ª Á¤ºÎ´Â ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥À» ½ÃÇàÇÏ°í µðÁöÅÐ °Ç°­ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÅëÇØ ¹ÙÀÌ¿À¸¶Ä¿ µµÀÔÀ» Áö¿øÇϰí ÀÖÀ¸¸ç, UC Davis School of MedicineÀÌ 2022³â¿¡ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é UC Davis Health°¡ ½ÃÇàÇÑ Digital Health Equity ProgramÀº ¿¬¹æÁ¤ºÎ·ÎºÎÅÍ 170¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» Áö¿ø¹Þ¾Ò½À´Ï´Ù. ÀÌ Á¤ºÎ ÀÚ±ÝÀº ºÏºÎ ͏®Æ÷´Ï¾Æ¿Í »õÅ©¶ó¸àÅä¿¡ °ÅÁÖÇÏ´Â »çȸÀû ¾àÀÚÀÇ ÀÇ·á ±â°ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â Áö¿ª µðÁöÅÐ °ø°ø °Ç°­ Ç÷§Æû °³¹ß¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

AliveCor Inc., Empatica, Inc., Huma, VivoSense¿Í °°Àº ½Å»ý ±â¾÷µéÀº Àμö, Á¦ÈÞ, ÆÄÆ®³Ê½Ê, ½ÅÁ¦Ç° Ãâ½Ã¿Í °°Àº Àü·«À» äÅÃÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù µðÁöÅÐ Çコ ±â¾÷ ÈÞ¸¶(Huma)´Â µðÁöÅÐ ÀÓ»ó½ÃÇè ºÐ¾ßÀÇ ¿ª·®À» È®´ëÇϱâ À§ÇØ ¾Ë¼¼µð½º(Alcedis)¸¦ ÀμöÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÀμöÀÇ ¸ñÀûÀº °³¹ß ÇÁ·Î¼¼½ºÀÇ ¿©·¯ ´Ü°è¿¡ °ÉÃÄ ÀÇ·á ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â °ÍÀÔ´Ï´Ù.

µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÀÓ»ó ¾÷¹«º° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Ä¡·á ºÐ¾ßº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer's or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer's disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â